Le notizie del giorno | 15 dicembre - Serale
- 27
Segui l'attualità dall'Europa e dal mondo. Ricevi le ultime notizie su economia, spettacolo, politica, cultura, viaggi. ALTRE ...
Euronews
Welcome to the official Euronews YouTube channel!
Around the clock, our team of 500 journalists of more than 30 different nationalities gathers news with impartial perspective, beyond the headlines content and voices from across Europe and the world. Our YouTube channel has all this and more, bringing you selected and original content from the world's most trusted news source.
Our mission is to empower people to form their own opinion. We trust in people’s intelligence and ability to make up their own mind and seek to provide our audience with the greatest diversity of viewpoints through journalism that is unapologetically impartial. We don’t trade in bias and outrage, we focus on facts, ideas, and solutions. We believe all views matter.
Euronews was born out of a will to create a strong independent European news channel in 1993. As the only international news media with a European perspective, Euronews is where the world turns to hear what Europe has to say.
Check us out on ⬇️
Lastest news
- MAPS Deadline: MAPS Investors with Losses in Excess of $100K Have Opportunity to Lead WM Technology, Inc. Securities Class Action Filed by The Rosen Law Firm
- FLUX IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Flux Power Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - FLUX
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages IMX Token Purchasers to Inquire About Immutable Securities Class Action Investigation
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX
- PACS Deadline: PACS Investors with Losses in Excess of $100K Have Opportunity to Lead PACS Group Inc. Securities Fraud Lawsuit
- Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China
Lastest videos